TRCT
LKFT

Tower Research Capital (TRC)’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Tower Research Capital (TRC)’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2M Buy
66,536
+65,988
+12,042% +$2.19M 0.05% 344
2025
Q4 		$17.9K Sell
548
-49
-8% -$1.58K ﹤0.01% 3184
2025
Q3 		$20.7K Sell
597
-78,538
-99% -$2.51M ﹤0.01% 3282
2025
Q2 		$2.21M Buy
79,135
+77,750
+5,614% +$2.08M 0.06% 293
2025
Q1 		$34.8K Buy
1,385
+555
+67% +$14K ﹤0.01% 2503
2024
Q4 		$22.8K Buy
830
+473
+132% +$13.2K ﹤0.01% 3087
2024
Q3 		$10.3K Sell
357
-5,122
-93% -$139K ﹤0.01% 3781
2024
Q2 		$136K Buy
5,479
+4,682
+587% +$133K ﹤0.01% 2363
2024
Q1 		$25.7K Sell
797
-1,137
-59% -$42.3K ﹤0.01% 2781
2023
Q4 		$78.6K Buy
1,934
+1,854
+2,318% +$68.2K ﹤0.01% 2824
2023
Q3 		$2.76K Sell
80
-5,126
-98% -$200K ﹤0.01% 5104
2023
Q2 		$212K Buy
5,206
+4,672
+875% +$191K 0.01% 1520
2023
Q1 		$20K Sell
534
-59
-10% -$2.42K ﹤0.01% 3422
2022
Q4 		$26K Sell
593
-540
-48% -$22.7K ﹤0.01% 2876
2022
Q3 		$49K Buy
1,133
+676
+148% +$34.6K ﹤0.01% 3169
2022
Q2 		$25K Sell
457
-2,058
-82% -$122K ﹤0.01% 3553
2022
Q1 		$156K Buy
2,515
+1,708
+212% +$105K ﹤0.01% 1912
2021
Q4 		$44K Sell
807
-2,772
-77% -$145K ﹤0.01% 2859
2021
Q3 		$188K Buy
3,579
+3,471
+3,214% +$206K ﹤0.01% 1877
2021
Q2 		$7K Sell
108
-1,686
-94% -$129K ﹤0.01% 4555
2021
Q1 		$138K Buy
1,794
+999
+126% +$92K ﹤0.01% 2323
2020
Q4 		$79K Sell
795
-1,526
-66% -$187K ﹤0.01% 2578
2020
Q3 		$329K Buy
2,321
+881
+61% +$147K ﹤0.01% 2098
2020
Q2 		$284K Buy
1,440
+652
+83% +$135K 0.01% 1491
2020
Q1 		$154K Sell
788
-54
-6% -$11.6K 0.01% 853
2019
Q4 		$174K Buy
842
+486
+137% +$89.8K 0.01% 646
2019
Q3 		$54K Buy
356
+107
+43% +$17.5K ﹤0.01% 1742
2019
Q2 		$32K Buy
249
+157
+171% +$18.6K ﹤0.01% 1854
2019
Q1 		$11K Sell
92
-15
-14% -$1.51K ﹤0.01% 2633
2018
Q4 		$10K Sell
107
-152
-59% -$15.4K ﹤0.01% 2463
2018
Q3 		$29K Sell
259
-169
-39% -$17.9K ﹤0.01% 2093
2018
Q2 		$39K Buy
428
+96
+29% +$9.31K ﹤0.01% 1993
2018
Q1 		$33K Sell
332
-1,156
-78% -$125K ﹤0.01% 1915
2017
Q4 		$140K Buy
1,488
+1,468
+7,340% +$139K 0.02% 719
2017
Q3 		$2K Buy
+20
New +$1.75K ﹤0.01% 3558
2017
Q2 		– Sell
-1,870
Closed -$161K – 2986
2017
Q1 		$161K Buy
+1,870
New +$135K 0.02% 337
2016
Q4 		– Sell
-304
Closed -$20K – 4033
2016
Q3 		$20K Buy
304
+119
+64% +$6.71K ﹤0.01% 1615
2016
Q2 		$11K Sell
185
-15
-8% -$754 ﹤0.01% 2723
2016
Q1 		$8K Buy
+200
New +$9.28K ﹤0.01% 2196
2015
Q4 		– Sell
-219
Closed -$9K – 4679
2015
Q3 		$9K Buy
+219
New +$12.6K ﹤0.01% 2385

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tower Research Capital (TRC)'s LKFT Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 12,042% in Q1 2026, buying an estimated $2.19M and bringing the position to 66,536 shares worth $2M. The position accounts for 0.05% of the portfolio, ranked #344.

Tower Research Capital (TRC) first reported a position in LKFT in Q3 2015 and has held it in 40 quarters since. The position peaked at $2.21M in Q2 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Tower Research Capital (TRC) held 66,536 shares of Lakefront Biotherapeutics American Depositary Shares worth $2M as of Q1 2026.
  • Tower Research Capital (TRC) bought 65,988 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $2.19M.
  • Lakefront Biotherapeutics American Depositary Shares made up 0.05% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #344 holding.
  • Tower Research Capital (TRC) first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2015 and has held it in 40 quarters since.
  • Tower Research Capital (TRC)'s Lakefront Biotherapeutics American Depositary Shares position peaked at $2.21M in Q2 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.